Drug Type Diagnostic radiopharmaceuticals, Radionuclide Drug Conjugates (RDC) |
Synonyms 64Cu-DOTA-AE105 |
Target |
Action inhibitors |
Mechanism uPAR inhibitors(Urokinase plasminogen activator surface receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Start Date01 Jun 2024 |
Sponsor / Collaborator [+1] |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of prostate | Phase 2 | Denmark | 01 Jun 2024 | |
Adenocarcinoma of prostate | Phase 2 | Sweden | 01 Jun 2024 | |
Localized Prostate Carcinoma | Phase 2 | Denmark | 01 Jun 2024 | |
Localized Prostate Carcinoma | Phase 2 | Sweden | 01 Jun 2024 | |
Neoplasms | Phase 1 | Denmark | 13 Sep 2015 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |